Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 72 | 12,335 | 46% |
| 2020 | 63 | 11,560 | 48% |
| 2021 | 57 | 11,779 | 51% |
| 2022 | 59 | 12,754 | 53% |
| 2023 | 58 | 13,355 | 55% |
| 2024 | 70 | 14,481 | 57% |
| 2025 from claims | – | 16,471 15,116–17,426 | 58% |
| 2026 forecast | – | 17,231 15,161–19,884 | 58% |
| 2027 forecast | – | 17,990 15,380–21,439 | 59% |
| 2028 forecast | – | 18,781 15,671–22,997 | 59% |
| 2029 forecast | – | 19,604 16,012–24,585 | 60% |
| 2030 forecast | – | 20,460 16,392–26,220 | 60% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 39% of the cases CMS names in New York; 37 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 51% hospital outpatient, 45% office. The share outside the hospital has moved +24 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~17,200 | ~700 | ~8,500 | ~8,000 |
| 2027 · ~18,000 | ~750 | ~8,700 | ~8,500 |
| 2028 · ~18,800 | ~800 | ~9,100 | ~8,900 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 48% (51% in 2025), office about 48% (45% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New Jersey | 47 | 11,826+17%/yr | +17%/yr | 7.7 | 65% | 21,200 in 2030+10%/yr |
| Pennsylvania | 30 | 9,758+2.6%/yr | +2.6%/yr | 4.2 | 75% | 13,200 in 2030+5.2%/yr |
| Massachusetts | 33 | 6,154+1.6%/yr | +1.6%/yr | 4.7 | 36% | 6,700 in 2030+1.4%/yr |
| Connecticut | 15 | 3,005+7.9%/yr | +7.9%/yr | 5.3 | 50% | 4,060 in 2030+5.1%/yr |
| New Hampshire | 12 | 1,375+11%/yr | +11%/yr | 4.4 | 20% | 1,740 in 2030+4%/yr |
| Rhode Island | 3 | 886−5.4%/yr | −5.4%/yr | 5.2 | 41% | 870 in 2030−0.4%/yr |
| Maine | 4 | 721−5.3%/yr | −5.3%/yr | 2.6 | 14% | 740 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 877 | 165,137−3.1%/yr | −3.1%/yr | 86.31.0× | 54% | 176,500 in 2030+1.1%/yr |
| Bone graft & orthobiologics | 21 | 796−5%/yr | −5%/yr | 0.40.9× | 1% | 810 in 2030+0.2%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in New York · Every state · Compare with New Jersey
Kerecis leads with 41% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 32 companies reported engagement with New York’s surgeons worth $1.4M in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.